TriSalus Life Sciences heads into its May 14 earnings with short sellers adding positions at the fastest rate in months — yet the lending market remains far too relaxed to suggest anything close to a squeeze.
Short interest has climbed steadily and meaningfully into the event. It rose 14% over the past week and nearly 18% over the past month, reaching roughly 2.9% of the free float. That rate of accumulation is the standout signal: bears have been adding through April and into May even as the stock gained 8% on the month to close at $4.56. The borrow market has barely pushed back — cost to borrow is just 0.89% annualised, essentially unchanged over the week, and availability is running at around 346% of current short interest. Plenty of shares remain in the lending pool, meaning new short positions are easy and cheap to open.
The analyst picture has been quiet, though the direction is cautious. Canaccord Genuity, the only active covering firm in recent months, slashed its target from $12 to $7 in early March — a meaningful cut that brought expectations into closer range of the current price. The consensus target of $9.20 is roughly double the trading price, but given the staleness of most underlying notes (the consensus was struck in late March), that headline gap warrants caution rather than excitement. All active ratings are Buy or equivalent, yet the sharp downward revision to the Canaccord target implies the bull case has narrowed. The company carries estimated annual revenue of around $57.7 million against a net loss approaching $21.3 million, with operating cash flow still negative — so profitability remains a future question, not a current fact. EPS surprise ranks in the 87th percentile historically, though forward EPS momentum scores in the bottom quartile, suggesting beats have not been accompanied by improving forward expectations.
One institutional development worth noting is fresh buying from index-adjacent names. BlackRock added 746,000 shares as of April 30, and Wasatch Advisors initiated a fresh 1.44 million-share position as of March 31. Those flows sit alongside a cluster of small executive share disposals in mid-March — the CEO sold $61,000 worth at $3.85, with several other C-suite officers trimming nominal positions at similar levels. None of the insider sales were large in dollar terms, and all carried the lowest significance rating, so they read more as routine equity-plan activity than directional conviction.
The earnings print is therefore less a test of whether revenue is growing and more a question of whether TriSalus can demonstrate a credible path to narrowing its operating losses at a pace that justifies the recent re-rating — and whether the accelerating short interest reflects a well-founded thesis or a crowded pre-event trade into thin liquidity.
See the live data behind this article on ORTEX.
Open TLSI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
